Dianthus Therapeutics (DNTH) to Release Earnings on Monday

Dianthus Therapeutics (NASDAQ:DNTH) is expected to be releasing its Q1 2026 results after the market closes on Monday, May 11th. Analysts expect Dianthus Therapeutics to post earnings of ($1.1029) per share and revenue of $0.4040 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%.The company had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.40 million. On average, analysts expect Dianthus Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Dianthus Therapeutics Price Performance

DNTH stock traded up $3.16 on Monday, reaching $90.58. 56,739 shares of the company were exchanged, compared to its average volume of 945,694. Dianthus Therapeutics has a 12 month low of $16.64 and a 12 month high of $96.50. The stock’s fifty day moving average price is $78.79 and its 200 day moving average price is $55.19. The firm has a market capitalization of $4.93 billion, a PE ratio of -22.09 and a beta of 1.18.

Analyst Ratings Changes

DNTH has been the topic of a number of research reports. Stifel Nicolaus set a $120.00 target price on shares of Dianthus Therapeutics in a research report on Monday, March 9th. Wedbush lifted their price target on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 10th. Raymond James Financial upgraded shares of Dianthus Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their price target for the stock from $63.00 to $123.00 in a research note on Tuesday, March 10th. Oppenheimer lifted their price target on shares of Dianthus Therapeutics to $145.00 and gave the stock an “outperform” rating in a research note on Monday, March 9th. Finally, Jefferies Financial Group set a $98.00 price target on shares of Dianthus Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $115.55.

Insider Activity

In other news, EVP Ryan Savitz sold 8,224 shares of the business’s stock in a transaction on Thursday, April 9th. The shares were sold at an average price of $89.84, for a total value of $738,844.16. Following the sale, the executive vice president owned 8,224 shares in the company, valued at approximately $738,844.16. The trade was a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marino Garcia sold 122,918 shares of the business’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $81.49, for a total transaction of $10,016,587.82. The SEC filing for this sale provides additional information. Insiders have sold a total of 323,021 shares of company stock worth $26,564,008 over the last 90 days. 3.02% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. acquired a new position in Dianthus Therapeutics during the 2nd quarter worth about $27,000. Caitong International Asset Management Co. Ltd acquired a new position in Dianthus Therapeutics during the 4th quarter worth about $40,000. Russell Investments Group Ltd. acquired a new position in Dianthus Therapeutics during the 3rd quarter worth about $64,000. Tower Research Capital LLC TRC lifted its position in Dianthus Therapeutics by 330.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in Dianthus Therapeutics by 36.9% during the 4th quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after buying an additional 542 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.